BMO Capital Reiterates Outperform on Sarepta Therapeutics (SRPT) Following Part-2 Data from Elevidys PhIII
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $200.00 price target on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
